Page 16 - Labatt BTRC Annual Report 2020-2021

YEAR IN REVIEW
Year in Review – Currently Held Grants
Dr. Sunit Das
Integrated nanotechnology and biomedical sciences library. Canadian Institutes of Health Research
Targeting heterogeneity in brain cancer.
Ontario Institute for Cancer Research
Targeting treatment resistance by modifying cancer cell identity in malignant brain tumours. Province of Ontario Early Researcher Award
Dr. Peter Dirks
Modeling brain cancer in regionally defined human neural stem cell system. Canadian Institutes of Health Research
Reimagining glioblastoma as a consequence of aberrant neural tissue repair. Canadian Cancer Society
The New Roads Team – Innovative approaches to curing brain tumours. Cancer Research UK
Targeting biological vulnerabilities of glioblastoma.
Cancer Research UK
Clinical translation of novel immune-based combination therapies for paediatric hypermutant cancers. Stand Up To Cancer
Targeting epigenetic dysregulation in pediatric cancers. Stand Up To Cancer
Epigenetic reorganization and differentiation of glioblastoma. Canadian Epigenetics, Environment and Health Research Consortium
Tackling childhood brain cancer at the root to improve survival and quality of life. Genome Canada
Stem cell related genesis and maintenance of glioblastoma. Canadian Institutes of Health Research
Cellular and genetic heterogeneity as a therapeutic hurdle and opportunity for Ontarians. Ontario Institute for Cancer Research
Chromatin proteins as drug targets for glioblastoma. The Brain Tumour Charity
Targeting brain tumour stem cell epigenetic and molecular networks. Stand Up To Cancer Canada
Functional genomic screen to identify drivers of human GBM. Terry Fox Research Institute
Functional and genomic clonal analysis of human glioblastoma. Canadian Institutes of Health Research
Dr. Cynthia Hawkins
Hsp90 inhibitor as a therapeutic strategy for diffuse intrinsic pontine glioma. Meagan’s HUG (Meagan Bebenek Foundation)
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ ERK pathways. Canadian Institutes of Health Research
Investigation of formyl peptide receptors as novel therapeutic targets in DIPG. b.r.a.i.n.child
16 IMAGINE 2020-21